Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications

References

• Bennett J M, Komrokji R S. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005; 10: 258–269
   PubMed Web of Science ®Google Scholar
• McKenna R W. Myelodysplasia and myeloproliferative disorders in children. Am J Clin Pathol 2004; 122(Suppl)58–69
   Google Scholar
• Pfeilstöcker M, Reisner R, Nösslinger T, Grüner H, Nowotny H, Tüchler H, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999; 106: 455–463
   PubMed Web of Science ®Google Scholar
• Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223–2231
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Raza A, Qawi H, Mehdi M, Mumtaz M, Galili N. Translational research in myelodysplastic syndromes. Rev Clin Exp Hematol 2004; 8: 2
   Google Scholar
• Hofmann W K, Koeffler H P. Important features of myelodysplastic syndrome. Int J Hematol 2002; 76(Suppl 2)222–227
   PubMed Web of Science ®Google Scholar
• Steensma D P, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95–120
   PubMed Web of Science ®Google Scholar
• Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J. Aging and genome maintenance: lessons from the mouse?. Science 2003; 299: 1355–1359
   PubMed Web of Science ®Google Scholar
• Capri M, Salvioli S, Sevini F, Valensin S, Celani L, Monti D. The genetics of human longevity. Ann N Y Acad Sci 2006; 1067: 252–263
   PubMed Web of Science ®Google Scholar
• Nisse C, Haguenoer J M, Grandbastien B, Preudhomme C, Fontaine B, Brillet J M. Occupational and environmental risk factors of the myelodysplastic syndromes in the north of France. Br J Haematol 2001; 112: 927–935
   PubMed Web of Science ®Google Scholar
• Loft S, Poulsen H E. Cancer risk and oxidative DNA damage in man. J Mol Med 1996; 74: 297–312
   PubMed Web of Science ®Google Scholar
• Hodkinson C F, O'Connor J M, Alexander H D, Bradbury I, Bonham M P, Hannigan B M. Whole blood analysis of phagocytosis, apoptosis, cytokine production, and leukocyte subsets in healthy older men and women: the ZENITH study. J Gerontol A Biol Sci Med Sci 2006; 61: 907–917
   PubMed Web of Science ®Google Scholar
• Fraga C G, Shigenaga M K, Park J W, Degan P, Ames B N. Oxidative damage to DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 1990; 87: 4533–4537
   PubMed Web of Science ®Google Scholar
• Farquhar M J, Bowen D T. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003; 77: 342–350
   PubMed Web of Science ®Google Scholar
• Haslberger A, Varga F, Karlic H. Recursive causality in evolution: a model for epigenetic mechanisms in cancer development. Med Hypotheses 2006; 67: 1448–1454
   PubMed Web of Science ®Google Scholar
• Johnson F B, Sinclair D A, Guarente L. Molecular biology of aging. Cell 1999; 96: 291–302
   PubMed Web of Science ®Google Scholar
• Kirkwood T B. Evolution of ageing. Nature 1977; 270: 301–304
   PubMed Web of Science ®Google Scholar
• Extermann M, Aapro M, Bernabei R, Cohen H J, Droz J P, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241–252
   PubMed Web of Science ®Google Scholar
• Mathers J C. Nutritional modulation of ageing: genomic and epigenetic approaches. Mech Ageing Dev 2006; 127: 584–589
   Google Scholar
• Panani A D, Roussos C. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. Cancer Lett 2006; 235: 177–190
   PubMed Web of Science ®Google Scholar
• Sole F, Luno E, Sanzo C, Espinet B, Sanz G F, Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168–1178
   PubMed Web of Science ®Google Scholar
• Haase D, Steidl C, Schanz J, Schabla R, Pfeilstöcker M, Nösslinger T, et al. Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS. Blood 2005; 106: 232
   Web of Science ®Google Scholar
• Fenaux P, Morel P, Lai J L. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996; 33: 127–138
   PubMed Web of Science ®Google Scholar
• Washington L T, Doherty D, Glassman A, Martins J, Ibrahim S, Lai R. Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. Leuk Lymphoma 2002; 43: 761–765
   PubMed Web of Science ®Google Scholar
• Pierre R V, Hoagland H C. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer 1972; 30: 889–894
   PubMed Web of Science ®Google Scholar
• Wiktor A, Rybicki B A, Piao Z S, Shurafa M, Barthel B, Maeda K, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11–16
   PubMed Web of Science ®Google Scholar
• Chen B, Zhao W L, Jin J, Xue Y Q, Cheng X, Chen X T, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19: 767–775
   PubMed Web of Science ®Google Scholar
• Hofmann W K, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler H P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553–3560
   PubMed Web of Science ®Google Scholar
• Dewald G H, Higgins R, Griffin C, Cherry A, Rowe J. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplasia: an Eastern Cooperative Oncology Group (ECOG) study. Blood 2000; 96: 148
   Web of Science ®Google Scholar
• Bolufer P, Barragan E, Collado M, Cervera J, Lopez J A, Sanz M A. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 2006; 30: 1471–1491
   PubMed Web of Science ®Google Scholar
• Silva Mdo C, Gaspar J, Duarte Silva I, Faber A, Rueff J. GSTM1, GSTT1, and GSTP1 genotypes and the genotoxicity of hydroquinone in human lymphocytes. Environ Mol Mutagen 2004; 43: 258–264
   PubMed Web of Science ®Google Scholar
• Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19: 1919–1928
   PubMed Web of Science ®Google Scholar
• Wolfler A, Erkeland S J, Bodner C, Valkhof M, Renner W, Leitner C, et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 2005; 105: 3731–3736
   PubMed Web of Science ®Google Scholar
• Balog A, Borbenyi Z, Gyulai Z, Molnar L, Mandi Y. Clinical importance of transforming growth factor-beta but not of tumor necrosis factor-alpha gene polymorphisms in patients with the myelodysplastic syndrome belonging to the refractory anemia subtype. Pathobiology 2005; 72: 165–170
   PubMed Web of Science ®Google Scholar
• Gyulai Z, Balog A, Borbenyi Z, Mandi Y. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung 2005; 52: 463–475
   PubMedGoogle Scholar
• Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 2000; 96: 3154–3160
   PubMed Web of Science ®Google Scholar
• Shi X, Shi W, Li Q, Song B, Wan M, Bai S, et al. A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells. EMBO Rep 2003; 4: 374–380
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones P A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457–463
   PubMed Web of Science ®Google Scholar
• Aoki E, Uchida T, Ohashi H, Nagai H, Murase T, Ichikawa A, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000; 14: 586–593
   PubMed Web of Science ®Google Scholar
• Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997; 90: 1403–1409
   PubMed Web of Science ®Google Scholar
• Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985–2990
   PubMed Web of Science ®Google Scholar
• Herman J G, Baylin S B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler K W, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997; 94: 2545–2550
   PubMed Web of Science ®Google Scholar
• Pfeilstöcker M, Karlic H, Wihlidal P, Nösslinger T, Pittermann E. Hypermethylation and reduced carnitine availability – a possible mechanism for downregulation of microsomal carnitine palmitoyltransferase (mCPT) in myelodysplastic syndromes (MDS). Blood 2006; 108: 748
   Web of Science ®Google Scholar
• Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 2006; 600: 46–57
   PubMed Web of Science ®Google Scholar
• Bender C M, Zingg J M, Jones P A. DNA methylation as a target for drug design. Pharm Res 1998; 15: 175–187
   PubMed Web of Science ®Google Scholar
• Ruter B, Wijermans P W, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 2004; 80: 128–135
   PubMed Web of Science ®Google Scholar
• Marciniak R, Guarente L. Human genetics. Testing telomerase. Nature 2001; 413: 370–371
   PubMed Web of Science ®Google Scholar
• Ram R, Uziel O, Lahav M. The importance of the telomere and telomerase system in hematological malignancies. Leuk Lymphoma 2005; 468: 1121–1135
   Web of Science ®Google Scholar
• Dimri G P, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363–9367
   PubMed Web of Science ®Google Scholar
• Chang E, Harley C B. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190–11194
   PubMed Web of Science ®Google Scholar
• Ohyashiki J H, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54: 3557–3560
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Iwama H, Yahata N, Tauchi T, Kawakubo K, Shimamoto T, et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 2001; 42: 291–299
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Kusec R, Rack K, Elliott P J, Atoyebi O, et al. Telomere length in myelodysplastic syndromes. Am J Hematol 1997; 56: 266–271
   PubMed Web of Science ®Google Scholar
• Ohshima K, Karube K, Shimazaki K, Kamma H, Suzumiya J, Hamasaki M, et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003; 44: 1339–1346
   PubMed Web of Science ®Google Scholar
• Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Apoptosis and prognostic factors in myelodysplastic syndromes. Leuk Lymphoma 2002; 43: 257–260
   PubMed Web of Science ®Google Scholar
• Mufti G J. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 543–557
   PubMed Web of Science ®Google Scholar
• Gurkan E, Tanriverdi K, Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk Res 2005; 29: 1131–1139
   PubMed Web of Science ®Google Scholar
• Holzenberger M, Kappeler L, De Magalhaes Filho C. IGF-1 signaling and aging. Exp Gerontol 2004; 39: 1761–1764
   Google Scholar
• Shimon I, Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995; 19: 233–240
   PubMed Web of Science ®Google Scholar
• Qi H, Xiao L, Lingyun W, Ying T, Yi-Zhi L, Shao-Xu Y, et al. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis. Ann Hematol 2006; 85: 95–101
   PubMed Web of Science ®Google Scholar
• Karlic H, Lohninger A, Laschan C, Lapin A, Bohmer F, Huemer M, et al. Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. J Mol Med 2003; 81: 435–442
   PubMed Web of Science ®Google Scholar
• Fillitz M, Karlic H, Tüchler H, Zeibig J, Spiegel W, Wihlidal P, et al. Does mRNA level of microsomal carnitine palmitoyltransferase predict yield of peripheral blood stem cell apheresis?. Ann Hematol 2006; 85: 386–393
   PubMed Web of Science ®Google Scholar
• Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol 2007; 69: 51–67
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu V W, Addessi C L, Sheffield D A, Linnane A W, Nagley P. Differential occurrence of mutations in mitochondrial DNA of human skeletal muscle during aging. Hum Mutat 1998; 11: 360–371
   PubMed Web of Science ®Google Scholar
• Chinnery P F, Samuels D C, Elson J, Turnbull D M. Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism?. Lancet 2002; 360: 1323–1325
   PubMed Web of Science ®Google Scholar
• Ogasawara Y, Nakayama K, Tarnowka M, McCoy J P, Kajigaya S, Levin B C, et al. Mitochondrial DNA spectra of single human CD34+ cells, T cells, B cells, and granulocytes. Blood 2005; 106: 3271–3284
   PubMed Web of Science ®Google Scholar
• Shin M G, Kajigaya S, Levin B C, Young N S. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 2003; 101: 3118–3125
   PubMed Web of Science ®Google Scholar
• Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265–278
   PubMed Web of Science ®Google Scholar
• Mundle S D, Ali A, Cartlidge J D, Reza S, Alvi S, Showel M M, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999; 60: 36–47
   PubMed Web of Science ®Google Scholar
• Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003; 27: 583–591
   PubMed Web of Science ®Google Scholar
• Parker J E, Mufti G J. The myelodysplastic syndromes: a matter of life or death. Acta Haematol 2004; 111: 78–99
   PubMed Web of Science ®Google Scholar
• Ricciardi M R, Petrucci M T, Gregorj C, Martini V, Levi A, De Cuia M R, et al. Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and interferon-alpha. Leuk Lymphoma 2004; 45: 1437–1443
   PubMed Web of Science ®Google Scholar
• Kalina U, Hofmann W K, Koschmieder S, Wagner S, Kauschat D, Hoelzer D, et al. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000; 28: 1158–1163
   PubMed Web of Science ®Google Scholar
• Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003; 44: 213–222
   PubMed Web of Science ®Google Scholar
• Arthur W T, Vernon R B, Sage E H, Reed M J. Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc Res 1998; 55: 260–270
   PubMed Web of Science ®Google Scholar
• Khorramizadeh M R, Tredget E E, Telasky C, Shen Q, Ghahary A. Aging differentially modulates the expression of collagen and collagenase in dermal fibroblasts. Mol Cell Biochem 1999; 194: 99–108
   PubMed Web of Science ®Google Scholar
• Hornebeck W, Emonard H, Monboisse J C, Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002; 12: 231–241
   PubMed Web of Science ®Google Scholar
• Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005; 75: 485–491
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Fracchiolla N S, Mazzeo L M, Silvestris I, Pomati M, Somalvico F, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 2005; 46: 1345–1351
   PubMed Web of Science ®Google Scholar
• Morgan M A, Reuter C W. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 2006; 85: 139–163
   PubMed Web of Science ®Google Scholar
• Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 2004; 28: 325–332
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• Steinmann G G, Klaus B, Müller-Hermelink H K. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 1985; 22: 563–575
   PubMed Web of Science ®Google Scholar
• Taub D D, Longo D L. Insights into thymic aging and regeneration. Immunol Rev 2005; 205: 72–93
   PubMed Web of Science ®Google Scholar
• de Vries E, de Bruin-Versteeg S, Comans-Bitter W M, de Groot R, Hop W C, Boerma G J, et al. Longitudinal survey of lymphocyte subpopulations in the first year of life. Pediatr Res 2000; 47: 528–557
   PubMed Web of Science ®Google Scholar
• Paolisso G, Barbieri M, Bonafe M, Franceschi C. Metabolic age modelling: the lesson from centenarians. Eur J Clin Invest 2000; 30: 888–894
   PubMed Web of Science ®Google Scholar
• Hamblin T J. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33: 150–162
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80: 268–279
   PubMed Web of Science ®Google Scholar
• Greenberg P L, Young N S, Gattermann N. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2002; 136–161
   PubMedGoogle Scholar
• Thomas X, Chelghoum Y. Cigarette smoking and acute leukemia. Leuk Lymphoma 2004; 45: 1103–1109
   PubMed Web of Science ®Google Scholar
• West R R, Stafford D A, White A D, Bowen D T, Padua R A. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000; 95: 2093–2097
   PubMed Web of Science ®Google Scholar
• Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology 2000; 11: 285–291
   PubMed Web of Science ®Google Scholar
• Vijg J. Somatic mutations and aging: a re-evaluation. Mutat Res 2000; 447: 117–135
   PubMed Web of Science ®Google Scholar
• Lahmann C, Bergemann J, Harrison G, Young A R. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet 2001; 357: 935–936
   PubMed Web of Science ®Google Scholar
• Moraitis D, Du B, De Lorenzo M S, Boyle J O, Weksler B B, Cohen E G, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005; 65: 664–670
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen M K, Christiansen D H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273–3279
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542–3552
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak M L, Arber D A, Niland J C, Nademanee A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593
   PubMed Web of Science ®Google Scholar
• Tester W J, Kinsella T J, Waller B, Makuch R W, Kelley P A, Glatstein E, et al. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol 1984; 2: 762–769
   PubMed Web of Science ®Google Scholar
• Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937–945
   PubMed Web of Science ®Google Scholar
• Cabantchik Z I, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277–287
   PubMed Web of Science ®Google Scholar
• Strom S S, Gu Y, Gruschkus S K, Pierce S A, Estey E H. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005; 19: 1912–1918
   PubMed Web of Science ®Google Scholar
• Yoshida K, Hirabayashi Y, Watanabe F, Sado T, Inoue T. Caloric restriction prevents radiation-induced myeloid leukemia in C3H/HeMs mice and inversely increases incidence of tumor-free death: implications in changes in number of hemopoietic progenitor cells. Exp Hematol 2006; 34: 274–283
   PubMed Web of Science ®Google Scholar
• Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996; 94: 116–119
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 34: 5358–5365
   Web of Science ®Google Scholar
• Nösslinger T, Tüchler H, Germing U, Valent P, Krieger O, Haase D, et al. Individualizing IPSS risk assessment in myelodysplastic syndromes by additionally taking into account age, gender and French-American-British (FAB) classification. Blood 2006; 108: 739
   Web of Science ®Google Scholar
• Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
   PubMed Web of Science ®Google Scholar
• Mufti G J, Stevens J R, Oscier D G, Hamblin T J, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–443
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta M G, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603
   PubMed Web of Science ®Google Scholar
• Sanz G F, Sanz M A, Vallespi T, Canizo M C, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408
   PubMed Web of Science ®Google Scholar
• Desole S S, Lussar M, Pirhofer U, Holzner C, Kemmler B, Sperner-Unterweger G, et al. Geriatric assessment of tumor patients in Austria. Onkologie 2006; 29(Suppl 3)221
   Google Scholar
• Aul C, Bowen D T, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71–86
   PubMed Web of Science ®Google Scholar
• Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14: 2–8
   PubMed Web of Science ®Google Scholar
• Agrelo R, Cheng W H, Setien F, Ropero S, Espada J, Fraga M F, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 2006; 103: 8822–8827
   PubMed Web of Science ®Google Scholar
• Cherian S, Bagg A. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. Hematology 2006; 11: 1–13
   PubMed Web of Science ®Google Scholar
• Rudolph K L, Chang S, Lee H W, Blasco M, Gottlieb G J, Greider C, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701–712
   PubMed Web of Science ®Google Scholar
• Fu C, Chen Z. Telomerase activity in myelodysplastic syndrome. Chin Med J 2002; 115: 1475–1478
   PubMed Web of Science ®Google Scholar
• Claessens Y E, Bouscary D, Dupont J M, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002; 99: 1594–1601
   PubMed Web of Science ®Google Scholar
• Razzaque M S, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006; 12: 298–305
   PubMed Web of Science ®Google Scholar
• Mellibovsky L, Diez A, Serrano S, Aubia J, Perez-Vila E, Marinoso M L, et al. Bone remodeling alterations in myelodysplastic syndrome. Bone 1996; 19: 401–405
   PubMed Web of Science ®Google Scholar
• Wu S, Xie G, Bai R, Wang Y, Zhu P. Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome. Chin Med J 1998; 111: 690–693
   PubMed Web of Science ®Google Scholar
• Vidal D O, Paixao V A, Brait M, Souto E X, Caballero O L, Lopes L F, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007; 31: 175–181
   PubMed Web of Science ®Google Scholar